BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results

MT Newswires Live

Yesterday

BridgeBio Oncology Therapeutics (BBOT) said Tuesday BBO-8520 plus pembrolizumab showed a 75% objective response rate at 500 mg once daily and 53% across dose levels in KRASG12C inhibitor-experienced NSCLC patients.

BBO-8520 monotherapy showed a 63% objective response rate and 100% disease control rate in second-line or later KRASG12C inhibitor-naive NSCLC patients. Of 28 patients eligible for six-month follow-up, 75% remained on treatment for more than six months.

The company said BBO-8520 was generally tolerable and manageable, with no grade 3 liver enzyme elevations reported in the monotherapy cohort.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2666704673"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666704673\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666704673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666704673","market":"us","top_or_hot":-1,"title":"BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results","media":"MT Newswires Live","content":"<html><body><p> BridgeBio Oncology <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BBOT) said Tuesday BBO-8520 plus pembrolizumab showed a 75% objective response rate at 500 mg once daily and 53% across dose levels in KRASG12C inhibitor-experienced NSCLC patients.</p><p>BBO-8520 monotherapy showed a 63% objective response rate and 100% disease control rate in second-line or later KRASG12C inhibitor-naive NSCLC patients. Of 28 patients eligible for six-month follow-up, 75% remained on treatment for more than six months.</p><p>The company said BBO-8520 was generally tolerable and manageable, with no grade 3 liver enzyme elevations reported in the monotherapy cohort.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBOT Reports BBO-8520 Data in NSCLC, Highlights Combination Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-09 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BridgeBio Oncology <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BBOT) said Tuesday BBO-8520 plus pembrolizumab showed a 75% objective response rate at 500 mg once daily and 53% across dose levels in KRASG12C inhibitor-experienced NSCLC patients.</p><p>BBO-8520 monotherapy showed a 63% objective response rate and 100% disease control rate in second-line or later KRASG12C inhibitor-naive NSCLC patients. Of 28 patients eligible for six-month follow-up, 75% remained on treatment for more than six months.</p><p>The company said BBO-8520 was generally tolerable and manageable, with no grade 3 liver enzyme elevations reported in the monotherapy cohort.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666704673","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666704673","pubTimestamp":1788902979,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BridgeBio Oncology Therapeutics  said Tuesday BBO-8520 plus pembrolizumab showed a 75% objective response rate at 500 mg once daily and 53% across dose levels in KRASG12C inhibitor-experienced NSCLC patients.BBO-8520 monotherapy showed a 63% objective response rate and 100% disease control rate in second-line or later KRASG12C inhibitor-naive NSCLC patients. Of 28 patients eligible for six-month follow-up, 75% remained on treatment for more than six months.The company said BBO-8520 was generally tolerable and manageable, with no grade 3 liver enzyme elevations reported in the monotherapy cohort.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BBOT":"BridgeBio Oncology Therapeutics, Inc"},"translate_title":"BBOT 报告 NSCLC 中的 BBO-8520 数据，强调组合结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBOT":1.5},"content_text":"BridgeBio Oncology Therapeutics (BBOT) said Tuesday BBO-8520 plus pembrolizumab showed a 75% objective response rate at 500 mg once daily and 53% across dose levels in KRASG12C inhibitor-experienced NSCLC patients.BBO-8520 monotherapy showed a 63% objective response rate and 100% disease control rate in second-line or later KRASG12C inhibitor-naive NSCLC patients. Of 28 patients eligible for six-month follow-up, 75% remained on treatment for more than six months.The company said BBO-8520 was generally tolerable and manageable, with no grade 3 liver enzyme elevations reported in the monotherapy cohort.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}